ZC3H13 Regulates Ferroptosis to Enhance Osteogenic Differentiation in Osteoporotic BMSCs.

IF 3.5 3区 医学 Q3 CELL & TISSUE ENGINEERING
Qiang Zhu, Zhezheng Chen, Ting Fu, Ya Lin, Xiaorong Lan, Jingang Xiao, Lin Liu
{"title":"ZC3H13 Regulates Ferroptosis to Enhance Osteogenic Differentiation in Osteoporotic BMSCs.","authors":"Qiang Zhu, Zhezheng Chen, Ting Fu, Ya Lin, Xiaorong Lan, Jingang Xiao, Lin Liu","doi":"10.1089/ten.tea.2024.0243","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objectives:</i></b> N6-methyladenosine (m<sup>6</sup>A) modification is critical in the regulation of osteoporosis (OP). Although ZC3H13 is an important m<sup>6</sup>A methyltransferase, its specific regulatory effects and mechanisms in osteoporosis are not yet fully understood. Therefore, we investigated the impact of ZC3H13 on the osteogenic potential of bone marrow-derived mesenchymal stem cells (BMSCs) in osteoporosis and attempted to elucidate its underlying mechanism. <b><i>Materials and Methods:</i></b> Western blotting, quantitative reverse transcription polymerase chain reaction, and immunohistochemical staining were used to identify changes in ZC3H13 and osteogenic factor (RUNX2 and OPN) expression in osteoporosis. Gain- and loss-of-function experiments were conducted to study the impact of ZC3H13 on the osteogenic differentiation of osteoporotic BMSCs (OP-BMSCs). Transcriptomic sequencing, transmission electron microscopy, and intraperitoneal injection of the ferroptosis inhibitor ferrostatin-1 (Fer-1) were used to elucidate the downstream mechanisms regulated by ZC3H13 in osteoporosis. In addition, rescue assays were performed to elucidate the underlying molecular mechanisms involved. <b><i>Results:</i></b> Here, we revealed that ZC3H13 was downregulated in OP-BMSCs and osteoporotic rat femurs, which correlated with the reduced osteogenic differentiation of OP-BMSCs. Functionally, ZC3H13 knockdown resulted in decreased osteogenic differentiation of the BMSCs, whereas ZC3H13 overexpression promoted the osteogenic differentiation of the OP-BMSCs. Furthermore, ZC3H13 knockdown was closely related to metal ion binding, reduced cell proliferation, and altered mitochondrial morphology. Treatment with the ferroptosis inhibitor Fer-1 partially reversed osteoporotic phenotypes <i>in vivo</i>. Mechanistically, ZC3H13 was shown to promote osteogenic differentiation in OP-BMSCs by inhibiting ferroptosis. <b><i>Conclusions:</i></b> Our study revealed that ZC3H13 promoted the osteogenic differentiation of BMSCs by inhibiting ferroptosis in osteoporosis. This research offers a reliable theoretical foundation for predicting and treating osteoporosis.</p>","PeriodicalId":56375,"journal":{"name":"Tissue Engineering Part A","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tissue Engineering Part A","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/ten.tea.2024.0243","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: N6-methyladenosine (m6A) modification is critical in the regulation of osteoporosis (OP). Although ZC3H13 is an important m6A methyltransferase, its specific regulatory effects and mechanisms in osteoporosis are not yet fully understood. Therefore, we investigated the impact of ZC3H13 on the osteogenic potential of bone marrow-derived mesenchymal stem cells (BMSCs) in osteoporosis and attempted to elucidate its underlying mechanism. Materials and Methods: Western blotting, quantitative reverse transcription polymerase chain reaction, and immunohistochemical staining were used to identify changes in ZC3H13 and osteogenic factor (RUNX2 and OPN) expression in osteoporosis. Gain- and loss-of-function experiments were conducted to study the impact of ZC3H13 on the osteogenic differentiation of osteoporotic BMSCs (OP-BMSCs). Transcriptomic sequencing, transmission electron microscopy, and intraperitoneal injection of the ferroptosis inhibitor ferrostatin-1 (Fer-1) were used to elucidate the downstream mechanisms regulated by ZC3H13 in osteoporosis. In addition, rescue assays were performed to elucidate the underlying molecular mechanisms involved. Results: Here, we revealed that ZC3H13 was downregulated in OP-BMSCs and osteoporotic rat femurs, which correlated with the reduced osteogenic differentiation of OP-BMSCs. Functionally, ZC3H13 knockdown resulted in decreased osteogenic differentiation of the BMSCs, whereas ZC3H13 overexpression promoted the osteogenic differentiation of the OP-BMSCs. Furthermore, ZC3H13 knockdown was closely related to metal ion binding, reduced cell proliferation, and altered mitochondrial morphology. Treatment with the ferroptosis inhibitor Fer-1 partially reversed osteoporotic phenotypes in vivo. Mechanistically, ZC3H13 was shown to promote osteogenic differentiation in OP-BMSCs by inhibiting ferroptosis. Conclusions: Our study revealed that ZC3H13 promoted the osteogenic differentiation of BMSCs by inhibiting ferroptosis in osteoporosis. This research offers a reliable theoretical foundation for predicting and treating osteoporosis.

ZC3H13调控铁下沉促进骨质疏松性骨髓间充质干细胞成骨分化
目的:n6 -甲基腺苷(m6A)修饰在骨质疏松症(OP)的调节中起关键作用。虽然ZC3H13是一种重要的m6A甲基转移酶,但其在骨质疏松症中的具体调控作用和机制尚不完全清楚。因此,我们研究了ZC3H13对骨质疏松症骨髓间充质干细胞(BMSCs)成骨潜能的影响,并试图阐明其潜在机制。材料与方法:采用Western blotting、定量逆转录聚合酶链反应、免疫组化染色检测骨质疏松组织中ZC3H13、成骨因子(RUNX2、OPN)表达的变化。通过功能增益和功能缺失实验研究ZC3H13对骨质疏松性骨髓间充质干细胞(OP-BMSCs)成骨分化的影响。通过转录组测序、透射电镜和腹腔注射铁下垂抑制剂铁抑素-1 (ferr -1)来阐明ZC3H13在骨质疏松症中调控的下游机制。此外,进行了救援试验以阐明所涉及的潜在分子机制。结果:我们发现ZC3H13在op -骨髓间充质干细胞和骨质疏松大鼠股骨中表达下调,与op -骨髓间充质干细胞成骨分化减少有关。功能上,ZC3H13敲低导致骨髓间充质干细胞成骨分化减弱,而ZC3H13过表达促进op -骨髓间充质干细胞成骨分化。此外,ZC3H13基因敲低与金属离子结合、细胞增殖减少和线粒体形态改变密切相关。铁下垂抑制剂fer1在体内部分逆转骨质疏松表型。在机制上,ZC3H13通过抑制铁下垂来促进OP-BMSCs的成骨分化。结论:我们的研究表明ZC3H13通过抑制骨质疏松症的铁下垂促进骨髓间充质干细胞的成骨分化。本研究为骨质疏松症的预测和治疗提供了可靠的理论依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Tissue Engineering Part A
Tissue Engineering Part A Chemical Engineering-Bioengineering
CiteScore
9.20
自引率
2.40%
发文量
163
审稿时长
3 months
期刊介绍: Tissue Engineering is the preeminent, biomedical journal advancing the field with cutting-edge research and applications that repair or regenerate portions or whole tissues. This multidisciplinary journal brings together the principles of engineering and life sciences in the creation of artificial tissues and regenerative medicine. Tissue Engineering is divided into three parts, providing a central forum for groundbreaking scientific research and developments of clinical applications from leading experts in the field that will enable the functional replacement of tissues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信